Literature DB >> 22918641

Tear lacritin levels by age, sex, and time of day in healthy adults.

Kyle Seifert1, Natasha C Gandia, Jennifer K Wilburn, Kraig S Bower, Rose K Sia, Denise S Ryan, Michael L Deaton, Katherine M Still, Veronica C Vassilev, Gordon W Laurie, Robert L McKown.   

Abstract

PURPOSE: Several small proteomic studies suggest that the prosecretory tear protein lacritin may be selectively downregulated in dry eye syndrome and in blepharitis, yet little information is available about normal baseline levels. This study assessed lacritin levels in tears from healthy individuals and addressed whether they differ according to sex, age, or time of day.
METHODS: Rabbit antibodies against lacritin N-terminal peptide EDASSDSTGADPAQEAGTS (Pep Lac N-Term) were generated and characterized against human recombinant lacritin and N-65 truncation mutant. Basal tears were collected from 66 healthy individuals ranging in age from 18 to 52 years, and at four times during one 24-hour period from 34 other individuals. Lacritin levels were then analyzed by ELISA and Western blotting.
RESULTS: Anti-Pep Lac N-Term bound lacritin, but not truncation mutant N-65 that lacks the N-terminal antigenic site. Tear lacritin levels followed a normal distribution with a mean of 4.2 ± 1.17 ng/100 ng total tear protein. Levels differed little by age or sex, and decreased slightly between 4 and 8 hours in a 24-hour cycle. Tear-blocking effects were minimal, as suggested by spiking of tears with recombinant lacritin.
CONCLUSIONS: Anti-Pep Lac N-Term-detectable lacritin comprises ~4.2 ng/100 ng total tear protein in healthy individuals, with no significant differences between males and females or among individuals between 18 and 52 years old. Levels decrease slightly in the late afternoon. These findings provide a baseline for future immunodiagnostic studies of lacritin in dry eye and other ocular diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918641      PMCID: PMC3460390          DOI: 10.1167/iovs.11-8729

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  39 in total

1.  Group II PLA(2) content of tears in normal subjects.

Authors:  K M Saari; V Aho; V Paavilainen; T J Nevalainen
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

2.  Survey of preferred tests for diagnosis of the tear film and dry eye.

Authors:  D R Korb
Journal:  Cornea       Date:  2000-07       Impact factor: 2.651

3.  Variability of tear protein levels in normal young adults: diurnal (daytime) variation.

Authors:  V Ng; P Cho; F Wong; Y Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-04       Impact factor: 3.117

4.  Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.

Authors:  Benjamin D Sullivan; Leslie A Crews; Barış Sönmez; Maria F de la Paz; Ebru Comert; Victor Charoenrook; Aline L de Araujo; Jay S Pepose; Michael S Berg; Valerie P Kosheleff; Michael A Lemp
Journal:  Cornea       Date:  2012-09       Impact factor: 2.651

5.  cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland.

Authors:  S Sanghi; R Kumar; A Lumsden; D Dickinson; V Klepeis; V Trinkaus-Randall; H F Frierson; G W Laurie
Journal:  J Mol Biol       Date:  2001-06-29       Impact factor: 5.469

6.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

7.  Normal tear protein profiles and age-related changes.

Authors:  J I McGill; G M Liakos; N Goulding; D V Seal
Journal:  Br J Ophthalmol       Date:  1984-05       Impact factor: 4.638

8.  The relations between tear fluid concentrations of lysozyme, tear-specific prealbumin and lactoferrin.

Authors:  P T Janssen; O P van Bijsterveld
Journal:  Exp Eye Res       Date:  1983-06       Impact factor: 3.467

9.  Age- and gender-related differences in human lacrimal fluid peroxidase activity.

Authors:  Giordana Marcozzi; Veronica Liberati; Federica Madia; Marco Centofanti; Giuseppe de Feo
Journal:  Ophthalmologica       Date:  2003 Jul-Aug       Impact factor: 3.250

View more
  14 in total

Review 1.  Lacritin and the tear proteome as natural replacement therapy for dry eye.

Authors:  Roy Karnati; Diane E Laurie; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2013-06-12       Impact factor: 3.467

2.  Detection of prosecretory mitogen lacritin in nonprimate tears primarily as a C-terminal-like fragment.

Authors:  Diane E Laurie; Rebecca K Splan; Kari Green; Katherine M Still; Robert L McKown; Gordon W Laurie
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-12       Impact factor: 4.799

Review 3.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

4.  A cleavage-potentiated fragment of tear lacritin is bactericidal.

Authors:  Robert L McKown; Erin V Coleman Frazier; Kaneil K Zadrozny; Andrea M Deleault; Ronald W Raab; Denise S Ryan; Rose K Sia; Jae K Lee; Gordon W Laurie
Journal:  J Biol Chem       Date:  2014-06-18       Impact factor: 5.157

5.  Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results.

Authors:  Valerie Yu; Dhruva Bhattacharya; Andrew Webster; Aditi Bauskar; Charles Flowers; Martin Heur; Shravan K Chintala; Tatsuo Itakura; Mark R Wilson; Joseph T Barr; Shinwu Jeong; Mingwu Wang; M Elizabeth Fini
Journal:  Ocul Surf       Date:  2018-08-02       Impact factor: 5.033

6.  A thermo-responsive protein treatment for dry eyes.

Authors:  Wan Wang; Aarti Jashnani; Suhaas R Aluri; Joshua A Gustafson; Pang-Yu Hsueh; Frances Yarber; Robert L McKown; Gordon W Laurie; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2014-12-03       Impact factor: 9.776

7.  Tissue transglutaminase is a negative regulator of monomeric lacritin bioactivity.

Authors:  Francisco Velez V; Jeffrey A Romano; Robert L McKown; Kari Green; Liwen Zhang; Ronald W Raab; Denise S Ryan; Cindy M L Hutnik; Henry F Frierson; Gordon W Laurie
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-01       Impact factor: 4.799

8.  Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.

Authors:  Trinka Vijmasi; Feeling Y T Chen; Suganthalakshmi Balasubbu; Marianne Gallup; Robert L McKown; Gordon W Laurie; Nancy A McNamara
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-17       Impact factor: 4.799

9.  Corneal Expression of SLURP-1 by Age, Sex, Genetic Strain, and Ocular Surface Health.

Authors:  Sudha Swamynathan; Emili E Delp; Stephen A K Harvey; Chelsea L Loughner; Leela Raju; Shivalingappa K Swamynathan
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

10.  Lacritin rescues stressed epithelia via rapid forkhead box O3 (FOXO3)-associated autophagy that restores metabolism.

Authors:  Ningning Wang; Keith Zimmerman; Ronald W Raab; Robert L McKown; Cindy M L Hutnik; Venu Talla; Milton F Tyler; Jae K Lee; Gordon W Laurie
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.